-+ 0.00%
-+ 0.00%
-+ 0.00%

RenovoRx says TAMP study shows reduced tumor activity in pancreatic cancer patients

PUBT·04/14/2026 12:32:59
Listen to the news
RenovoRx says TAMP study shows reduced tumor activity in pancreatic cancer patients
  • RenovoRx reported clinical data on its TAMP targeted chemotherapy delivery platform that were presented April 13, 2026 at Society of Interventional Radiology Annual Scientific Meeting.
  • Study from Moffitt Cancer Center indicated local delivery of gemcitabine near tumor site could support treatment response in locally advanced pancreatic cancer while limiting systemic toxicity.
  • Post-treatment PET/CT imaging showed reduced tumor metabolic activity, suggesting response even when tumor size changed little.
  • Results were positioned as supportive evidence for RenovoRx’s ongoing Phase III TIGeR-PaC trial of intra-arterial gemcitabine delivered via RenovoCath for locally advanced pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140830PRIMZONEFULLFEED9689177) on April 14, 2026, and is solely responsible for the information contained therein.